Filtered By:
Therapy: Statin Therapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 15003 results found since Jan 2013.

Antiplatelet and Statin Treatment Is Not Associated With Reduced Myocardial Infarction After High-Risk Vascular Procedures
Medical management (MM) with antiplatelet (AP) and statin therapy is recommended for most patients undergoing vascular surgery. We evaluated the preoperative use of these on postoperative myocardial infarction (MI) in patients undergoing high-risk procedures within the Vascular Quality Initiative (VQI).
Source: Journal of Vascular Surgery - November 21, 2014 Category: Surgery Authors: Randall R. DeMartino, Andrew W. Hoel, Adam W. Beck, John W. Hallett, Shipra Arya, Gilbert H. Upchurch, Jack L. Cronenwett, Philip P. Goodney Tags: Abstract from the Thirty-Ninth Annual Meeting of the Southern Association for Vascular Surgery Source Type: research

Participation in the Vascular Quality Initiative is associated with improved perioperative medication use, which is associated with longer patient survival
Medical management (MM) with antiplatelet (AP) and statin therapy is recommended for most patients undergoing vascular surgery and has been advocated by the Vascular Quality Initiative (VQI). We analyzed the effect of VQI participation on perioperative (preoperative and postoperative) MM use over time and the effect of discharge MM on patient survival.
Source: Journal of Vascular Surgery - January 16, 2015 Category: Surgery Authors: Randall R. De Martino, Andrew W. Hoel, Adam W. Beck, Jens Eldrup-Jorgensen, John W. Hallett, Gilbert R. Upchurch, Jack L. Cronenwett, Philip P. Goodney, Vascular Quality Initiative Tags: Clinical Paper Source Type: research

Preoperative antiplatelet and statin treatment was not associated with reduced myocardial infarction after high-risk vascular operations in the Vascular Quality Initiative
Medical management with antiplatelet (AP) and statin therapy is recommended for nearly all patients undergoing vascular surgery to reduce cardiovascular events. We assessed the association between preoperative use of AP and statin medications and postoperative in-hospital myocardial infarction (MI) in patients undergoing high-risk open surgery.
Source: Journal of Vascular Surgery - September 22, 2015 Category: Surgery Authors: Randall R. De Martino, Adam W. Beck, Andrew W. Hoel, John W. Hallett, Shipra Arya, Gilbert R. Upchurch, Jack L. Cronenwett, Philip P. Goodney, Vascular Quality Initiative Tags: Clinical Paper Source Type: research

Risk Factors for Suboptimal Utilization of Statins and Antiplatelet Therapy in Patients Undergoing Revascularization for Symptomatic Peripheral Arterial Disease
The Vascular Study Group of Greater New York (VSGGNY) database was used to identify all patients undergoing peripheral vascular intervention or lower extremity bypass for peripheral arterial disease (PAD; 2011-2013).
Source: Journal of Vascular Surgery - April 20, 2018 Category: Surgery Authors: A.J. Meltzer, A. Sedrakyan, P.H. Connolly, S. Ellozy, D.B. Schneider, Vascular Study Group of Greater Tags: Underutilization of statins and antiplatelet therapy in patients undergoing vascular intervention Source Type: research

Effects of Anacetrapib in Patients With Atherosclerotic Vascular Disease
Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo.
Source: Journal of Vascular Surgery - December 18, 2017 Category: Surgery Authors: HPS3/TIMI55 –REVEAL Collaborative Group, L. Bowman, J.C. Hopewell, F. Chen, K. Wallendszus, W. Stevens Tags: Vascular vantage point Source Type: research

Effects of Statin and Antiplatelet Therapy Noncompliance and Intolerance on Patient Outcomes Following Vascular Surgery
Prior studies have evaluated the effects of statin and antiplatelet (AP) medications on the vascular surgery patient population. Although the benefits of statin and AP use are well-described, there is a paucity of research into the specific outcomes of patients who are unable to take the medication owing to intolerance or noncompliance. Our goal is to examine the outcomes of intolerant patients and to compare to those who are noncompliant.
Source: Journal of Vascular Surgery - December 19, 2018 Category: Surgery Authors: Johnston L. Moore, Zdenek Novak, Graeme E. McFarland, Mark A. Patterson, Marc A. Passman, Emily L. Spangler, Benjamin J. Pearce, Adam W. Beck Tags: Abstract from the 2019 Southern Association for Vascular Surgery Annual Meeting Source Type: research

Non-high-density lipoprotein cholesterol and treatment targets in vascular surgery patients
DISCUSSION: Among vascular surgery patients, over half did not meet non-HDL targets. These results suggest that we may be vastly under-performing adequate medical optimization with only about one-fourth of patients on a statin at their final encounter and approximately one-tenth of patients being treated with a high-intensity statin. With recent evidence supporting non-HDL as a valuable measurement for atherosclerotic risk, there is potential to optimize medical management beyond current high-intensity statin therapy. Further investigation is needed regarding the risk of adverse events between patients treated with these v...
Source: Vascular - September 16, 2022 Category: Surgery Authors: Drew J Braet Kian Pourak Vibav Mouli Itai Palmon Dan Dinh Nicholas H Osborne Chandu Vemuri Eric J Brandt Source Type: research

Is targeting microRNAs the philosopher's stone for vascular disease?
Abstract MicroRNAs (miRs) are small non-coding regulatory RNAs that control gene expression. They are involved in the pathogenesis of several diseases, including vascular and cardiac diseases. Their involvement is related to alterations of lipid metabolism, endothelial dysfunction, vascular smooth muscle cell phenotype, atherosclerosis-related low-grade inflammation of the arteries, cardiac hypertrophy or remodelling and heart failure. The manipulation of miRs may eventually be used to prevent or treat vascular or cardiac disease. Available drugs (some statins and renin-angiotensin-system inhibitors, alone or in c...
Source: Current Vascular Pharmacology - March 31, 2015 Category: Drugs & Pharmacology Authors: Athyros VG, Katsiki N, Karagiannis A Tags: Curr Vasc Pharmacol Source Type: research

Oxidative Stress In Chronic Vascular Disease: From Prediction To Prevention.
Abstract This review article is intended to describe the strong relationship between oxidative stress and vascular disease. Reactive oxygen species (ROS) play an important role in the pathogenesis of vascular disease: oxidative stress is intimately linked to atherosclerosis, through oxidation of LDL and endothelial dysfunction, to diabetes, mainly through advanced glycation end-products (AGEs)/receptor for AGE (RAGE) axis impairment, protein kinase C (PKC), aldose reductase (AR) and NADPH oxidase (NOX) dysfunction, and to hypertension, through renin-angiotensin system (RAS) dysfunction. Several oxidative stress bi...
Source: Vascular Pharmacology - September 9, 2015 Category: Drugs & Pharmacology Authors: Santilli F, D'Ardes D, Davì G Tags: Vascul Pharmacol Source Type: research

Early Diagnosis of Vascular Cognitive Impairment Leads to Improved Treatment of Vascular Risk Factors (P2.095)
Conclusions:Medical management of vascular risk factors improves in patients with undiagnosed early VCI following a diagnosis of VaMCI and implementation of educational and caregiver strategies. These results suggest that early diagnosis and increased education and supervision regarding treatment through an enhanced partnership with patients and families may benefit individuals at higher risk for future cerebrovascular events.Study Supported by:American Heart Association (15GRNT25270010), NIH (NIGMS U54GM104938) and the VA Clinical Science Research & Development Service (CX000340).Disclosure: Dr. Kirkpatrick has nothin...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Kirkpatrick, A., Vincent, A., Ross, E., Prodan, C. Tags: Vascular Disease and Dementia Source Type: research

Efficacy of statin on vascular access patency in diabetic hemodialysis patients.
CONCLUSIONS: Statin treatment could be associated with improved vascular access dysfunction among diabetic hemodialysis patients. PMID: 28604988 [PubMed - as supplied by publisher]
Source: The Journal of Vascular Access - June 14, 2017 Category: Surgery Tags: J Vasc Access Source Type: research

Statin therapy improved long-term prognosis in patients with major non-cardiac vascular surgeries: a systematic review and meta-analysis.
CONCLUSIONS: This meta-analysis demonstrated that statin therapy was associated with improved survival rates and patency rates and with reduced cardiovascular or stroke morbidities in patients who underwent non-cardiac vascular surgeries. PMID: 29953967 [PubMed - as supplied by publisher]
Source: Vascular Pharmacology - June 25, 2018 Category: Drugs & Pharmacology Authors: Yu W, Wang B, Zhan B, Li Q, Li Y, Zhu Z, Yan Z Tags: Vascul Pharmacol Source Type: research